Apex Fundrock Limited (MISL) Form 8.3 - Advanced Medical Solutions Group PLC - Opening Position Disclosure 31-March-2025 / 14:12 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient....
Feature article: Hardman & Co Healthcare Index, 2024 – Tough year for Life Sciences By Dr Martin Hall The main function of the HHI is to monitor the performance, and to highlight the attractiveness, of life sciences investments over the long term, and to try to identify those stocks that have disruptive technologies that consistently allow them to outperform both the index and the markets. Many of the 53 constituents of the index are high-risk, with micro-capitalisations and a long way from pro...
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the third year running, despite generally good returns in global markets, particularly in the US, performance in 2024 was poor, not helped by the capital-intensive nature of the sector. The HHI fell 17.7% to 398.9, underperforming all its benchmarks – FTSE 100 (+5.7%), FTSE All-Share (5.6%) and the FTSE AIM All-Share Index (-5...
A director at Advanced Medical Solutions Group maiden bought 48,864 shares at 205p and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (...
Dish of the day Joiners: No joiners today. Leavers: Egdon Resources has left AIM. What’s cooking in the IPO kitchen?** Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Admission delayed. Announced ITF 6 July: Blackpoint Biotech plc, a medical can...
15 March 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv...
While AMS’ full year results were broadly in line with expectations, the mix wasn’t quite as anticipated with US LiquiBand sales weaker than expected. The reason for the shortfall was that AMS has completed a strategic review of its US LiquiBand business and decided to move from three to two partners, with the partner that is exiting stage left running down stock levels in H2FY22. Although we understand the rationale for this move, we think that it significantly increases forecast risk in the sh...
In our view the acquisition of Connexicon probably won’t move the needle for AMS. The fit is OK, but we think there is a defensive element to the deal and AMS will need to deliver significant revenue growth to support the purchase price. We’ve updated our forecasts and the impact on FY23 EPS is neutral with around 1% accretion to FY24. Our TP is unchanged and we remain buyers, but doubt yesterday’s news will act a material catalyst.
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
We see two issues on the horizon for Advanced Medical Solutions that investors should be aware of, though we currently have no plans to change our fair value. We remain fans of this narrow-moat business and its strategy of shifting to higher-margin branded products mainly used in the surgical suite. On one hand, General Electric’s impending acquisition of wound care company Acelity could hurt AMS’s OEM segment. We surmise Acelity is one of AMS’s OEM clients, based on Acelity’s filings th...
We see two issues on the horizon for Advanced Medical Solutions that investors should be aware of, though we currently have no plans to change our fair value. We remain fans of this narrow-moat business and its strategy of shifting to higher-margin branded products mainly used in the surgical suite. On one hand, General Electric’s impending acquisition of wound care company Acelity could hurt AMS’s OEM segment. We surmise Acelity is one of AMS’s OEM clients, based on Acelity’s filings th...
Advanced Medical Solutions has been facing headwinds in its OEM advanced wound care business, which showed up in financial results halfway through the fiscal year. We have already baked in a low-single-digit year-over-year decline for the OEM segment for the full fiscal year, and are leaving our fair value estimate unchanged for now. Challenges on the OEM front have stemmed from two main factors. First, it seems reimbursement conditions in Europe have become more challenging and tenders are more...
Advanced Medical Solutions Group plc: Acquisition of Sealantis Advanced Medical Solutions Group plc ("AMS", the “Company” or the "Group") Acquisition of Sealantis Acquisition enhances AMS’s access to internal surgery market opportunitiesInnovative technology platform and products to enter the US$ 1 billion internal sealants marketFirst product expected to enter European market from H1 2021Significant potential for multiple additional internal sealant products and indications Winsford, UK, 31 January 2019: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound c...
Advanced Medical Solutions has been facing headwinds in its OEM advanced wound care business, which showed up in financial results halfway through the fiscal year. We have already baked in a low-single-digit year-over-year decline for the OEM segment for the full fiscal year, and are leaving our fair value estimate unchanged for now. Challenges on the OEM front have stemmed from two main factors. First, it seems reimbursement conditions in Europe have become more challenging and tenders are more...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.